Jonathan Young Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 10,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $53.81, for a total transaction of $538,100.00. Following the completion of the transaction, the chief operating officer now owns 251,147 shares in the company, valued at approximately $13,514,220.07. This trade represents a 3.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jonathan Young also recently made the following trade(s):

• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00.
• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total value of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total value of $321,300.00.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO traded down $0.74 during trading on Friday, hitting $54.21. The company had a trading volume of 851,309 shares, compared to its average volume of 2,119,158. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -14.46 and a beta of -0.11. The stock has a fifty day simple moving average of $33.04 and a two-hundred day simple moving average of $30.05. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a fifty-two week low of $17.84 and a fifty-two week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, research analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in shares of Akero Therapeutics in the second quarter valued at approximately $565,000. The Manufacturers Life Insurance Company increased its holdings in shares of Akero Therapeutics by 26.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company's stock worth $2,514,000 after buying an additional 22,195 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in Akero Therapeutics by 12.4% in the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company's stock valued at $574,000 after acquiring an additional 2,200 shares during the last quarter. Creative Planning acquired a new stake in Akero Therapeutics during the third quarter worth $371,000. Finally, Rheos Capital Works Inc. raised its position in Akero Therapeutics by 27.8% in the third quarter. Rheos Capital Works Inc. now owns 276,000 shares of the company's stock valued at $7,918,000 after purchasing an additional 60,000 shares during the period.

Analyst Upgrades and Downgrades

AKRO has been the subject of several recent research reports. HC Wainwright lifted their price target on Akero Therapeutics from $50.00 to $72.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Canaccord Genuity Group lifted their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Citigroup lifted their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Finally, Morgan Stanley increased their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics presently has a consensus rating of "Buy" and an average price target of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.